The latest update (28 January 2021) includes the following addition and revision:
biosafety aspects for working with antigen-detecting rapid diagnostic test;
handling new variants of SARS-CoV-2 in the laboratory;
updated assay decontamination before disposal;
personal protectiv...e equipment (PPE) for specimen collection;
addressing chemical hazards and their safe disposal; and
the fourth edition of the WHO Laboratory Biosafety Manual (LBM4) is now available and the terminology in this guidance was aligned with the LBM4.
more
The first update of the ECDC ventilation guidance document contains:
key new findings that emphasise four bundles of NPIs to reduce the risk of SARS-CoV-2 transmission in closed spaces;
updated references on the evidence of transmission in closed spaces;
recommendations based on the n...ew evidence and on national and international guidance; and
an overview of national guidance ventilation documents in the context of COVID-19 based on an inquiry sent to ECDC’s National Focal Points (NFPs) for Preparedness and Response and NFPs for Influenza and other respiratory diseases.
more
Острая респираторная вирусная инфекция (ОРВИ) – острое
инфекционное заболевание респираторного тракта, проявляющееся
воспалением верхних дыхательных путей, в б...ольшинстве случаев
завершающееся спонтанным выздоровлением. ОРВИ, как правило, протекает с
катаральными симптомами (насморком, кашлем, болью в горле и др.),
признаками общей интоксикации, субфибрильной, реже фибрильной,
лихорадкой.
Основными возбудителями ОРВИ являются вирусы гриппа типа А и В,
респираторно-синцитиальный вирус (РСВ), вирусы парагриппа, риновирусы,
аденовирусы, человеческие метапневмовирусы, бокавирусы, сезонные
коронавирусы. Вирусы, способные вызывать тяжелые пневмонии, такие как
MERS-CoV и SARS-CoV-2 (возбудитель новой коронавирусной инфекции
COVID-19), могут клинически протекать как сезонные ОРВИ. Также
необходимо помнить, что ОРВИ могут иметь сочетанную этиологию, когда в
развитии инфекционного процесса участвует несколько возбудителей. (версия 2 16.04.2020)
medical treatment for acute respiratory viral infections in outpatient practice during the COVID-19 epidemic
more
MEDBOX Issue Brief no. 7, Dec. 2020
Die Impfung gegen die Ausbreitung des SARS-CoV-2-Virus stellt einen Meilenstein in der Bekämpfung der Pandemie dar. Für den Erfolg der Impfung unabdingbar ist eine gute Kommunikation und Aufklärung der Bevölkerung. Im Folgenden sind einige Informationen zur I...mpfstrategie, Durchführung der Impfung, ethische Überlegungen, sowie Aufklärungsmaterialien in deutscher und englischer Sprache aufgelistet
more
Limited coverage of laboratory services and long turnaround times from real-time reverse transcription-polymerase chain reaction (rRT-PCR) for the detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has been insufficient to meet the demands in many African countries in response... to the COVID-19 pandemic. Rapid antigen diagnostic tests (AgRDTs) are potentially useful as they can inform healthcare workers and individuals of their infection status at point-of-care testing
more
The latest update (28 January 2021) includes the following addition and revision:
biosafety aspects for working with antigen-detecting rapid diagnostic test;
handling new variants of SARS-CoV-2 in the laboratory;
updated assay decontamination before disposal;
personal protectiv...e equipment (PPE) for specimen collection;
addressing chemical hazards and their safe disposal; and
the fourth edition of the WHO Laboratory Biosafety Manual (LBM4) is now available and the terminology in this guidance was aligned with the LBM4.
more
Contact tracing – along with robust testing, isolation and care of cases – is a key strategy for interrupting chains of transmission of SARS-CoV-2 and reducing mortality associated with COVID-19.
El rastreo de contactos, junto con las pruebas diagnósticas sólidas, el aislamiento y la atención de casos, es una estrategia fundamental para interrumpir las cadenas de transmisión del SARS-CoV-2 y reducir la mortalidad causada por la COVID-19.
A Organização Pan-Americana da Saúde, em seu esforço constante e permanente para apoiar os países das Américas, apresenta este documento para facilitar a formulação de uma estratégia de comunicação de riscos e participação comunitária (CRPC) para a vacinação contra o SARS-CoV-2. O in...tuito é contribuir para o fortalecimento das capacidades de comunicação e planejamento dos ministérios e secretarias de saúde, bem como de outros órgãos responsáveis pela comunicação na área das novas vacinas contra a COVID-19 nas Américas.
Available in English, Spanish and Portuguese
more
21 Dec 2021. Slideset updated regularly to include the latest data and guidance on COVID-19 vaccines, including implications of emerging SARS-CoV-2 variants
Orientations provisoires, 28 janvier 2021
Dans cette version mise à jour des orientations sur la sécurité biologique en laboratoire en rapport avec le SARS-CoV-2, le virus responsable de la maladie à coronavirus 2019 (COVID-19), les points suivants ont été ajoutés : aspects de... sécurité biologique relatifs à la réalisation des tests diagnostiques rapides antigéniques, manipulation des nouveaux variants du SARS-CoV-2 au laboratoire, mise à jour de la décontamination des tests avant leur élimination, équipement de protection individuelle (EPI) pour le prélèvement d’échantillons et, même s’ils ne concernent pas directement la sécurité biologique, dangers chimiques et leur élimination en toute sécurité.
more
Ziel dieser qualitativen Studie ist eine Situationsanalyse der Regelungen und Maßnahmen auf lokaler Ebene, die zur Prävention und Eindämmung der SARSCoV-2-Ausbreitung in SU für Geflüchtete ergriffen wurden.
10 May 2021. Manufactureres:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vecto...r vaccine against coronavirus disease 2019 (COVID-19). The vaccine expresses the SARS-CoV-2 spike protein gene, which instructs the host cells to produce the protein of the S-antigen unique to SARS-CoV-2, allowing the body to generate an immune response and to retain that information in memory immune cells. Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) irrespective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more
BMZ Papier 1
Gesundheit ist nicht nur Voraussetzung für ein selbstbestimmtes Leben, sondern auch essenziell für die gesellschaftliche und nachhaltige wirtschaftliche Entwicklung in unseren Partnerländern. Die gegenwärtige COVID-19 Pandemie zeigt, welche Gefahren von Infektionskrankheiten ausge...-hen. Der Erreger der Pandemie SARS-CoV-2 gibt auch einen Hinweis auf die Bedeutung zoono-tischer, also zwischen Tier und Mensch übertragbarer, Krankheiten. Es ist zu erwarten, dass diese Art von Erregern in der Zukunft noch häufiger auftreten wird. Eine wachsende Weltbevölkerung, Klimawandel, steigende Mobilität, Vordringen des Menschen in bisher unberührte Lebensräume, industrielle Landwirtschaft und Nutztierhaltung sind Faktoren, die das Risiko für das Entstehen bzw. für eine schnelle Ausbreitung von Krankheitserregern erhöhen
more
Available in Arabic, Chinese, English, French, Russian and Spanish. You can download a summary of the main report and background documents!
The report demonstrates that the current system—at both national and international levels— was not adequate to protect people from COVID-19. The time it t...ook from the reporting of a cluster of cases of pneumonia of unknown origin in mid-late December 2019 to a Public Health Emergency of International Concern being declared was too long. February 2020 was also a lost month when many more countries could have taken steps to contain the spread of SARS-CoV-2 and forestall the global health, social, and economic catastrophe that continues its grip. The Panel finds that the system as it stands now is clearly unfit to prevent another novel and highly infectious pathogen, which could emerge at any time, from developing into a pandemic.
more
COVID-19: occupational health and safety for health workers: interim guidance, Interim guidance 2 February 2021
Health workers are at the front line of the COVID-19 outbreak response and as such are exposed to different hazards that put them at risk. Occupational hazards include exposure to SARS-C...oV-2 and other pathogens, violence, harassment, stigma, discrimination, heavy workload and prolonged use of personal protective equipment (PPE). This document provides specific measures to protect occupational health and safety of health workers and highlights the duties, rights and responsibilities for health and safety at work in the context of COVID-19.
more
sur la base des orientations actuelles de l’OMS, 31 may 2021. Aide mémoire
This aide-mémoire presents information on use and procurement of masks for community outreach interventions, with a focus on those for malaria, neglected tropical diseases, tuberculosis, HIV/AIDS and vaccine-preventable ...diseases. It details requirements for the different types of professionals involved (e.g. health workers, social mobilizers, data collectors, logisticians, insecticide spraying personnel, etc.), based on their level of risk of potential exposure to SARS-CoV-2.
more
sobre la base de las orientaciones actuales de la OMS, 31 de mayo de 2021. Memorando
This aide-mémoire presents information on use and procurement of masks for community outreach interventions, with a focus on those for malaria, neglected tropical diseases, tuberculosis, HIV/AIDS and vaccine-preve...ntable diseases. It details requirements for the different types of professionals involved (e.g. health workers, social mobilizers, data collectors, logisticians, insecticide spraying personnel, etc.), based on their level of risk of potential exposure to SARS-CoV-2.
more
Noch Wochen und Monate nach Erkrankung an COVID-19 können gesundheitliche Langzeitfolgen bestehen. Welche Symptome treten bei Long COVID auf? Wer kann betroffen sein? Wie lassen sich Spätfolgen einer Infektion mit dem Coronavirus SARS-CoV-2 vermeiden?
Introdução: A pandemia pela COVID-19 é menos incidente na população pediátrica quando comparada à adulta, sendo apenas 2% dos casos abaixo dos 20 anos. Recentemente, a infecção pelo SARS-CoV-2 em crianças e adolescentes está sendo associada a Síndrome Inflamatória Multissistêmica Pedi...trica (SIM-P), doença de Kawasaki-like. Objetivo: Relatar a ocorrência de uma das apresentações clínicas da COVID-19 na infância, a SIM-P, ressaltando suas manifestações clínicas, laboratoriais e manejo clínico.
more